Leukemia Home > Treanda Uses
Treanda Use for Treating Non-Hodgkin's LymphomaNon-Hodgkin's lymphoma is a general term used to describe a group of cancers of the lymphatic system, which is part of the body's immune system. It includes a large network of tissues and organs, such as the lymph nodes, spleen, and bone marrow, which make and store white blood cells. These white blood cells, called lymphocytes, help the body fight infection. Lymphoma can start almost anywhere lymphatic tissue is present.
Non-Hodgkin's lymphomas are a large, diverse group of cancers. In general, these cancers can be grouped based on how quickly they spread and the type of lymphocyte affected -- either B-cells or T-cells. Indolent cancers have a slow-growing course and normally cause fewer symptoms. Indolent NHL can become aggressive. Aggressive NHL is a fast-growing cancer and spreads more quickly throughout the body.
Treanda is approved to treat indolent B-cell non-Hodgkin's lymphoma. It is specifically used in people who became worse during or within six months of treatment with another medication known as rituximab (Rituxan®).
How Does It Work?Although the exact way Treanda works is unknown, it is thought to attach to DNA and cause damage. Because DNA is necessary for cancer cells to grow and divide, Treanda causes cell death.
Is It Safe for Children to Use Treanda?Treanda is not approved for use in children. In clinical studies, the medication appeared to be as safe for children as it is for adults. However, it has not been shown to be effective for the treatment of children. Talk to your child's healthcare provider about the risks and benefits of using this medication in children.
Can Older Adults Use It?Older adults can use Treanda. In clinical studies, the side effects were similar between people aged 65 and older and those younger than 65. Adults older than age 65 with NHL appeared to respond to the medication no differently than younger age groups.
Treanda may not work as well in older adults with CLL. In clinical studies, only 47 percent of individuals aged 65 and older with CLL responded to the medication, compared with 70 percent of individuals younger than age 65. People 65 years of age and older treated with Treanda were also disease-free for a shorter period of time than those younger than age 65 (12 months versus 19 months).